These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15982180)

  • 21. Identifying predictors of low adherence in patients with inflammatory bowel disease.
    Coenen S; Weyts E; Ballet V; Noman M; Van Assche G; Vermeire S; Van Emelen J; Ferrante M
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):503-7. PubMed ID: 26760588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to Medical Treatment in Inflammatory Bowel Disease Patients from a Referral Center in Bahia-Brazil.
    Andrade LD; Oliveira FA; Mariano VD; Santos MCA; Pereira FA; Dos Santos CIN; Fortes FML; Pimentel AM; Mota JA; Almeida NP; Surlo VC; Silva BC; Pacheco MP; Santana GO
    Biomed Res Int; 2020; 2020():5269493. PubMed ID: 33029512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
    Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
    Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
    van Staa TP; Card T; Logan RF; Leufkens HG
    Gut; 2005 Nov; 54(11):1573-8. PubMed ID: 15994215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases.
    Kluthe C; Tsui J; Spady D; Carroll M; Wine E; Huynh HQ
    Can J Gastroenterol Hepatol; 2018; 2018():4687041. PubMed ID: 29682493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review: the use of mesalazine in inflammatory bowel disease.
    Bergman R; Parkes M
    Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesalazine-induced psoriasis in patients with inflammatory bowel diseases.
    Di Cesare A; Fidanza R; Riitano A; Fargnoli MC; Peris K
    Eur J Dermatol; 2011; 21(5):784-5. PubMed ID: 21697068
    [No Abstract]   [Full Text] [Related]  

  • 29. 5-aminosalicylates in inflammatory bowel disease--the more the merrier?
    Forbes A
    Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1017-9. PubMed ID: 8680898
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical pharmacokinetics of slow release mesalazine.
    De Vos M
    Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of prebiotics and probiotics in therapeutic management of cryptogenetic inflammatory bowel disease].
    Marteau P; Seksik P
    Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C94-7. PubMed ID: 11787388
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesalazine for the treatment of inflammatory bowel disease.
    Criscuoli V; Modesto I; Orlando A; Cottone M
    Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease.
    Cappello M; Licata A; Calvaruso V; Bravatà I; Aiello A; Torres D; Della Corte V; Tuttolomondo A; Perticone M; Licata G; Craxì A; Cammà C
    Eur J Intern Med; 2017 Jan; 37():83-89. PubMed ID: 27773555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era.
    Campos S; Portela F; Sousa P; Sofia C
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1313-9. PubMed ID: 27501126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.
    Pearce CB; Duncan HD; Timmis L; Green JR
    Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):439-43. PubMed ID: 10783998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication-taking behavior in a cohort of patients with inflammatory bowel disease.
    Bernal I; Domènech E; Garcia-Planella E; Marín L; Mañosa M; Navarro M; Cabré E; Gassull MA
    Dig Dis Sci; 2006 Dec; 51(12):2165-9. PubMed ID: 17086434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores].
    Geboes K; Desreumaux P; Jouret A; Ectors N; Rutgeerts P; Colombel JF
    Gastroenterol Clin Biol; 1999 Oct; 23(10):1062-73. PubMed ID: 10592879
    [No Abstract]   [Full Text] [Related]  

  • 40. [Classical medications in the treatment of inflammatory bowel diseases].
    Duvnjak M; Bilić A; Barsić N; Tomasić V; Stojsavljević S
    Acta Med Croatica; 2013 Apr; 67(2):111-24. PubMed ID: 24471294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.